OPDIVO® (Nivolumab) with AVD

The FDA on March 20, 2026, approved OPDIVO® (Nivolumab) with Doxorubicin, Vinblastine, and Dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL). OPDIVO® is a product of Bristol Myers Squibb Company.